Rhythm Q2 2023 revenue $19.2M; BBS prescriptions top 425; eligible for $25M milestone payment

RHYTHM PHARMACEUTICALS, INC.

2023-Q2 EPS reported -$1.74 revenue$30,691,000

Q2 2023 net product revenue $19.2M (vs $2.3M Q2 2022); net loss $46.7M ($0.82/share).
Achieved commercial sales milestone under RIFA with HealthCare Royalty, eligible for final $25M tranche.
Over 125 new BBS prescriptions in Q2 2023; >425 since FDA approval in June 2022.
Phase 3 hypothalamic obesity trial enrollment expected by Q4 2023; IND for RM-718 by end of 2023.
Cash, cash equivalents and short-term investments $253.6M as of June 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RHYTHM PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $19.2 million.

Period: the second quarter ended June 30, 2023
Revenue: $19.2 million
Result: reported results

Exact text from the filing

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update -- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE

View on SEC.gov

Browse all earnings releases →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-086034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.